Obesity drug has no competitors on unexploited market, says Novo Nordisk
Executive Vice President cannot see any drug currently on the market that can compete with Novo Nordisk's recently approved Wegovy – but the company is still keeping its foot on the gas and launching quickly.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY CATHERINE BRETT
It isn't pressure from competitors that is making Novo Nordisk aim for "the fastest launch after approval ever" for its new drug Wegovy, which was approved by the FDA on Friday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Launch of obesity drug will be Novo Nordisk's fastest ever
For subscribers
FDA approves Novo Nordisk's semaglutide as obesity treatment
For subscribers
.jpg&w=384&q=75)
